All Outputs (3)

Long-term Effectiveness of Adjuvant Treatment with Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared with Dopamine Agonists among Patients with Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial (2021)
Journal Article
Gray, R., Patel, S., Ives, N., Rick, C., Woolley, R., Muzerengi, S., …Clarke, C. E. (2022). Long-term Effectiveness of Adjuvant Treatment with Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared with Dopamine Agonists among Patients with Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial. JAMA Neurology, 79(2), 131-140. https://doi.org/10.1001/jamaneurol.2021.4736

Importance: Many people with Parkinson disease (PD) develop motor complications that are uncontrolled by levodopa dose adjustment. Among these patients, it is uncertain which drug class is more effective as adjuvant therapy. Objective: To compare the... Read More about Long-term Effectiveness of Adjuvant Treatment with Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared with Dopamine Agonists among Patients with Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.

Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson’s disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial (2021)
Journal Article
Scobie, S., Jowett, S., Lambe, T., Patel, S., Woolley, R., Ives, N., …Sackley, C. (2021). Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson’s disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial. Pilot and Feasibility Studies, 7(1), Article 154. https://doi.org/10.1186/s40814-021-00888-y

Background: The PD COMM pilot randomised controlled trial compared Lee Silverman Voice Treatment (LSVT® LOUD) with standard NHS speech and language therapy (SLT) and a control arm in people with Parkinson’s disease (PwPD) with self-reported problems... Read More about Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson’s disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial.

Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease (2021)
Journal Article
McIntosh, E., Kent, S., Gray, A., Clarke, C. E., Williams, A., Jenkinson, C., …PD MED Collaborative Group. (2021). Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease. Movement Disorders, 36(9), 2136-2143. https://doi.org/10.1002/mds.28623

Background: The PD MED study reported small but persistent benefits in patient-rated mobility scores and quality of life from initiating therapy with levodopa compared with levodopa-sparing therapies in early Parkinson's disease (PD). Objectives: The... Read More about Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.